The 8-year data may hold value for TAVI—the newest Sapien valve uses the same tissue—but many other variables differ.

A new method of alerting clinical care providers holds promise for increasing treatment and improving survival for patients with severe aortic stenosis (AS), a valvular heart condition that can be ...

Compared with usual care, a system of electronic provider notification more often enabled patients diagnosed with severe ...

Aortic dissection is a life-threatening medical condition in which a tear occurs in the major artery (aorta) that carries ...

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Mar. 31, 2025. Recent Highlights. Q1 ...

For patients with symptomatic aortic regurgitation at high surgical risk, a transcatheter aortic valve replacement system ...

The material is employed in a range of Edwards’ surgical and transcatheter valves, including versions of the Inspiris, Mitris ...

Mark Wilterding; Mark Wilterding Senior Vice President, Investor Relations and Treasurer; Edwards Lifesciences Corp. Bernard Zovighian; President, Chief Executive Of ...

Vivasure hope to find room in a competitive market with its surtureless implant that is absorbed 180 days after vessel ...

For young Indians grappling with aortic valve disease, the Ross procedure offers a lifeline—one that restores vitality ...

Piper Sandler upgraded Edwards Lifesciences (EW) to Overweight from Neutral with a price target of $80, up from $73. The firm sees a “better ...

Edwards Lifesciences raised its 2025 sales forecast on Wednesday after a quarterly beat, driven by robust demand for its artificial heart valves and other medical equipment. The company has revised ...